23:57:54 EST Fri 13 Dec 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Nurexone Biologic Inc
Symbol NRX
Shares Issued 55,341,700
Close 2024-01-16 C$ 0.265
Market Cap C$ 14,665,551
Recent Sedar Documents

Nurexone begins spinal cord research with Inteligex

2024-01-17 13:20 ET - News Release

Dr. Lior Shaltiel reports

NUREXONE AND INTELIGEX KICK OFF CHRONIC SPINAL CORD INJURY RESEARCH FOR MULTI-BILLION DOLLAR HEALTHCARE MARKET

Nurexone Biologic Inc. has shared several updates.

The collaborative agreement between NurExone and Inteligex Inc. ("Inteligex"), announced in October 2023, to expand the Company's portfolio, is now officially underway. This collaboration, aimed at combining Inteligex's more than twenty years of experience in cell-based therapies and NurExone's innovative exosome platform to develop therapies for patients with chronic spinal cord injuries, was approved for grant funding, to be disbursed over the course of the next two years, by the Israel-Canada bilateral Eureka program.

Dr. Lior Shaltiel, CEO of NurExone, expressed his excitement about the kick-off of this project stating, "This collaboration reiterates the importance and utility of the ExoTherapy platform in developing drug delivery systems of the future. As part of this collaboration, we will use our platform to produce and load exosomes from Inteligex's cell line to deliver combination regenerative therapy for Spinal Cord Injury (SCI) patients. This win-win collaboration will expand our potential markets and is in line with our belief of patient, first."

Dr. Paul Bradshaw, CEO of Inteligex, stated that "Spinal cord injury is the single most expensive healthcare condition in the world. I believe that a combinatorial multi-faceted approach to treatment of chronic SCI like the one in this project can both make a difference in patient's lives and save the healthcare system billions of dollars. Moreover, if the therapy has an easy delivery method, we can expand to countries where there is a massive barrier to any therapy or treatment and do a bit of good for humanity."

NurExone Announces Engagement Agreement with bullVestor

The Company has entered into an agreement (the "Agreement") with bullVestor Medien GmbH ("BullVestor") to assist with and enhance awareness of the Company's products and services using advertising and communications, some of which may constitute investor relations activities pursuant to the policies of the TSX Venture Exchange. The advertising and communications will occur in German-speaking countries (Germany, Austria and Switzerland).

The Agreement is effective for four months from the effective date and the total consideration payable to BullVestor is CAD$300,000 on the effective date. The consideration does not include any securities of the Company. BullVestor does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest. Aside from this engagement, the Company does not have any relationship with BullVestor.

BullVestor is located in Austria.

About NurExone Biologic Inc. NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology. For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn , Twitter , Facebook , or YouTube .

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.